Because of the aforementioned favorable pharmacokinetic characteristics (long half-life and tumor distribution) of albumin as a drug carrier, many attempts have been made to improve that of anti-cancer small molecule drugs by albumin conjugation [4,5,10,11,12,13,14]. Here, ALB is linked to neoplasm.